Bin Cao, Vice President and Director, Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital
Country of Residence: China
Vice President of China-Japan Friendship Hospital
Director of Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital
Vice Director of National Center for Respiratory Medicine
Professor of Capital Medical University
Professor of Tsinghua University-Peking University Joint Center for Life Sciences.
President-elect of Chinese Thoracic Society (CTS)
Director of Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital
Vice Director of National Center for Respiratory Medicine
Professor of Capital Medical University
Professor of Tsinghua University-Peking University Joint Center for Life Sciences.
President-elect of Chinese Thoracic Society (CTS)
Dr. Cao is a senior expert in respiratory infections, with his research interests including(1) Epidemiology, clinical characteristics, and treatment of viral pneumonia,(2) Molecular and cellular basis of the pathogenesis of influenza and COVID-19, (3) Diagnosis and treatment strategy and drug resistance of infections by drug-resistant pathogens,(4) Immune damage and protective mechanism of viral pneumonia.
Academic Contributions
Dr. Cao has published more than 200 peer reviewed articles and reviews, among which 8 representative pa-pers are published in Lancet or NEJM. Five papers are listed as Highly Cited Paper in ESI and 10 papers are recommended by F1000Prime and 4 papers are cited by WHO or NIH guidelines. Dr. Cao has been intesive-ly engaged in frontline clinical work in Wuhan since the COVID-19 outbreak. He firstly reported clinical characteristics of COVID-19 and risk factors for severe disease. He is also leading the antiviral clinical trials in China, including Remdesivir and lopinavir-ritonavir.
Dr. Cao has published more than 200 peer reviewed articles and reviews, among which 8 representative pa-pers are published in Lancet or NEJM. Five papers are listed as Highly Cited Paper in ESI and 10 papers are recommended by F1000Prime and 4 papers are cited by WHO or NIH guidelines. Dr. Cao has been intesive-ly engaged in frontline clinical work in Wuhan since the COVID-19 outbreak. He firstly reported clinical characteristics of COVID-19 and risk factors for severe disease. He is also leading the antiviral clinical trials in China, including Remdesivir and lopinavir-ritonavir.
